AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12100762 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine-dobutamine
Number of subjects: 16
Study 12100762 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 16
Study 12100762 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 16
Study 10225503 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery plus eye movements
Number of subjects: 71
Study 10225503 — intervention group
Group type: COMPARATOR
Intervention: Imagery alone
Number of subjects: 71
Study 8561662 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant stimulus condition (same erotic slide on repeated trials)
Number of subjects: 74
Study 8561662 — intervention group
Group type: EXPERIMENTAL
Intervention: Varied stimuli condition (various erotic slides)
Number of subjects: 74
Study 8561662 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated erotic stimulation followed by novel erotic stimulus
Number of subjects: 74
Study 8561662 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial EMG (physiological marker of emotional experience)
Number of subjects: 74
Study 1964751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (low molecular weight heparin) subcutaneously (120 anti-FXa U/kg) twice daily
Number of subjects: 119
Study 1964751 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (SH) as continuous intravenous infusion (480 IU kg‐1 day‐1)
Number of subjects: 119
Study 1964751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin
Number of subjects: 119
Study 1964751 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (SH)
Number of subjects: 119
Study 1964751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin and Standard heparin (SH)
Number of subjects: 119
Study 492872 — intervention group
Group type: EXPERIMENTAL
Intervention: low conflict (speed emphasized)
Number of subjects: 60
Study 492872 — intervention group
Group type: EXPERIMENTAL
Intervention: low conflict (accuracy emphasized)
Number of subjects: 60
Study 492872 — intervention group
Group type: EXPERIMENTAL
Intervention: intermediate conflict
Number of subjects: 60
Study 492872 — intervention group
Group type: EXPERIMENTAL
Intervention: high conflict
Number of subjects: 60
Study 30548279 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Education Program Pertaining to Sexual Myths
Number of subjects: 1178
Study 30548279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1178
Study 29040012 — intervention group
Group type: EXPERIMENTAL
Intervention: ALLIC 2002 protocol treatment for patients with Down syndrome
Number of subjects: 41
Study 29040012 — intervention group
Group type: COMPARATOR
Intervention: ALLIC 2002 protocol treatment for patients without Down syndrome
Number of subjects: 41
Study 25133492 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month moderate intensity walking intervention (three times a week, 40 minutes per session, supervised and home-based)
Number of subjects: 121
Study 25133492 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 121
Study 23828112 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion measuring relative blood flow
Number of subjects: 7
Study 23828112 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion measuring relative blood volume
Number of subjects: 7
Study 23828112 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion measuring relative capillary permeability
Number of subjects: 7
Study 23828112 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion measuring relative MTT
Number of subjects: 7
Study 21138617 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil therapy
Number of subjects: 25
Study 18503774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day for the first month and 8 mg/day thereafter; n = 32)
Number of subjects: 63
Study 18503774 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 63
Study 17591662 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education supplemented with individual clinic‐based counselling
Number of subjects: 901
Study 17591662 — intervention group
Group type: COMPARATOR
Intervention: Peer education only
Number of subjects: 901
Study 12841927 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac SR (400 mg/day)
Number of subjects: 64
Study 12841927 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (100 mg/day)
Number of subjects: 64
Study 12841927 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac SR
Number of subjects: 64
Study 12841927 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 64
Study 10885603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (methotrexate 100 mg/m2 and cisplatin 50 mg/m2 for 3 cycles at 2-week intervals)
Number of subjects: 204
Study 10885603 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (XRT)
Number of subjects: 204
Study 10885603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 204
Study 9368438 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure (John O. Butler Co.) denture adhesive paste
Number of subjects: 25
Study 9368438 — intervention group
Group type: COMPARATOR
Intervention: Other four denture adhesive pastes
Number of subjects: 25
Study 1408479 — intervention group
Group type: EXPERIMENTAL
Intervention: High titer Edmonston-Zagreb vaccine at 5 to 6 months of age
Number of subjects: 0
Study 1408479 — intervention group
Group type: COMPARATOR
Intervention: Standard titer Schwarz vaccine at 8 to 9 months of age
Number of subjects: 0
Study 1408479 — intervention group
Group type: COMPARATOR
Intervention: High titer Biken-CAM vaccine at 8 to 9 months of age
Number of subjects: 0
Study 1408479 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 0
Study 4062396 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antibiotic therapy (trimethoprim-sulfamethoxazole and erythromycin)
Number of subjects: 22
Study 4062396 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate open lung biopsy
Number of subjects: 22
Study 30244671 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation factor score
Number of subjects: 290
Study 30244671 — intervention group
Group type: EXPERIMENTAL
Intervention: High carotenoids and low interleukin-18 factor
Number of subjects: 290
Study 27729174 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine stored at elevated temperatures (25 °C for up to six months or 30 °C for three months)
Number of subjects: 0
Study 27729174 — intervention group
Group type: COMPARATOR
Intervention: Cold-chain stored vaccine (2–8 °C)
Number of subjects: 0
Study 24114367 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education
Number of subjects: 74
Study 22395923 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management intervention for COPD with ongoing support for 12 months.
Number of subjects: 464
Study 22395923 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful self-management (42% of intervention group classified as successful self managers).
Number of subjects: 464
Study 22395923 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life measures (secondary outcome).
Number of subjects: 464
Study 20445161 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 448
Study 20445161 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further treatment)
Number of subjects: 448
Study 20445161 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal surgical staging
Number of subjects: 448
Study 20445161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoptimal surgical staging
Number of subjects: 448
Study 18041606 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint aroma
Number of subjects: 144
Study 18041606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ylang-ylang aroma
Number of subjects: 144
Study 18041606 — intervention group
Group type: COMPARATOR
Intervention: No aroma control
Number of subjects: 144
Study 16048260 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPP (1 dwell amino acids, 1 dwell icodextrin, and two dwells bicarbonate/lactate-buffered glucose-based solution)
Number of subjects: 63
Study 16048260 — intervention group
Group type: COMPARATOR
Intervention: SPD (standard PD regimen; 4 dwells glucose-/lactate-based)
Number of subjects: 63
Study 16048260 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPP
Number of subjects: 63
Study 16048260 — intervention group
Group type: COMPARATOR
Intervention: SPD
Number of subjects: 63
Study 12443582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 224
Study 12443582 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 224
Study 10500056 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg every 8 weeks)
Number of subjects: 73
Study 10500056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8744663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine infusion (15 micrograms/kg/h)
Number of subjects: 60
Study 8744663 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 60
Study 8744663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (nalbuphine and saline)
Number of subjects: 60
Study 1834049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (400 micrograms daily)
Number of subjects: 49
Study 1834049 — intervention group
Group type: COMPARATOR
Intervention: Danazol (600 mg daily)
Number of subjects: 49
Study 7074641 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by six courses of MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 177
Study 7074641 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 177
Study 30117359 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) test
Number of subjects: 51
Study 30117359 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait test utilizing OptoGait system
Number of subjects: 51
Study 28917715 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias modification procedure
Number of subjects: 0
Study 27435799 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg circulatory occlusion (occlusion)
Number of subjects: 48
Study 24375428 — intervention group
Group type: EXPERIMENTAL
Intervention: Williams LifeSkills Training (WLST)
Number of subjects: 66
Study 24375428 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention alone (control group)
Number of subjects: 66
Study 22776810 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% (group LB)
Number of subjects: 90
Study 22776810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-adrenaline 1% with 1:200,000 (group LA)
Number of subjects: 90
Study 22776810 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 90
Study 19401905 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk'n device (Home Pulsed Light)
Number of subjects: 34
Study 17463418 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 2.5 mg vitamin D
Number of subjects: 192
Study 17463418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 14995984 — intervention group
Group type: EXPERIMENTAL
Intervention: DX‐9065a
Number of subjects: 175
Study 14995984 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 175
Study 11591229 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-miscible retinyl palmitate (112 mg)
Number of subjects: 9
Study 11591229 — intervention group
Group type: COMPARATOR
Intervention: Oil-soluble retinyl palmitate (112 mg)
Number of subjects: 9
Study 9517717 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible light-cured bonding material (Sequence)
Number of subjects: 32
Study 9517717 — intervention group
Group type: COMPARATOR
Intervention: Chemically cured bonding material (System 1+)
Number of subjects: 32
Study 11271260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (DHPG) 3 mg/kg q 12 h for 2 weeks, plus CMV-hyperimmunglobulin (1 ml/kg per week for 6 weeks) if CMV+ donor
Number of subjects: 20
Study 11271260 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control, 18 patients, aged 53 ± 10 years)
Number of subjects: 20
Study 3122967 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg in the morning
Number of subjects: 162
Study 3122967 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 162
Study 30602649 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs (DSNP)
Number of subjects: 80
Study 30602649 — intervention group
Group type: COMPARATOR
Intervention: ZNPs (DZNP)
Number of subjects: 80
Study 30602649 — intervention group
Group type: COMPARATOR
Intervention: TNPs (DTNP)
Number of subjects: 80
Study 30602649 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (E)
Number of subjects: 80
Study 30602649 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (D)
Number of subjects: 80
Study 30602649 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs (ESNP)
Number of subjects: 80
Study 28110919 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (Xylocaine gauze applied for 2 minutes)
Number of subjects: 44
Study 28110919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water gauze applied for 2 minutes)
Number of subjects: 44
Study 28110919 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 44
Study 28110919 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety levels (measured by MDAS)
Number of subjects: 44
Study 25673087 — intervention group
Group type: EXPERIMENTAL
Intervention: LB30870 60 mg
Number of subjects: 16
Study 25673087 — intervention group
Group type: EXPERIMENTAL
Intervention: LB30870 120 mg
Number of subjects: 16
Study 25673087 — intervention group
Group type: EXPERIMENTAL
Intervention: LB30870 (various doses)
Number of subjects: 16
Study 25673087 — intervention group
Group type: EXPERIMENTAL
Intervention: LB30870 (doses above 15 mg)
Number of subjects: 16
Study 25673087 — intervention group
Group type: COMPARATOR
Intervention: LB30870 (60 mg)
Number of subjects: 16
Study 25673087 — intervention group
Group type: EXPERIMENTAL
Intervention: LB30870 (up to 240 mg)
Number of subjects: 16
Study 24284841 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone
Number of subjects: 100
Study 24284841 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone
Number of subjects: 100
Study 24284841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (40 mg and 20 mg)
Number of subjects: 100
Study 21052021 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB (amlodipine)
Number of subjects: 44
Study 21052021 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (losartan)
Number of subjects: 44
Study 21052021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CCB and ARB
Number of subjects: 44
Study 18444815 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole under directly observed therapy
Number of subjects: 361
Study 16472979 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate (CHO) solution
Number of subjects: 32
Study 16472979 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-g essential amino acid (EAA) mixture
Number of subjects: 32
Study 16472979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CHO+EAA supplement
Number of subjects: 32
Study 16472979 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 32
Study 14512130 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 loratadine 5‐mg tablets + ambroxol 30‐mg tablets (Formulation A)
Number of subjects: 30
Study 14512130 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 loratadine 10‐mg tablet (Formulation C)
Number of subjects: 30
Study 14512130 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ambroxol 30‐mg tablets (Formulation B)
Number of subjects: 30
Study 11251432 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32
Study 11251432 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 32
Study 9506640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysate formula (Alimentum)
Number of subjects: 23
Study 9506640 — intervention group
Group type: COMPARATOR
Intervention: Conventional infant formula (Similac)
Number of subjects: 23
Study 7924865 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative parenteral nutritional support (PNS) for 5 days, yielding 117 Kj.kg‐1.d‐1 of non‐protein calories and 0.15g.kg‐1.d‐1 of nitrogen.
Number of subjects: 19
Study 7924865 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with 5‐Fu at 8‐10mg.kg‐1.d‐1 for 5 days and mitomycin C at 6‐8mg.d‐1 on the first and fifth day.
Number of subjects: 19
Study 7924865 — intervention group
Group type: EXPERIMENTAL
Intervention: PNS plus chemotherapy (5‐Fu and mitomycin C) as in Groups A and B.
Number of subjects: 19
Study 3254831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 22
Study 3254831 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 22
Study 31524941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice a day) plus Aspirin (100 mg once a day)
Number of subjects: 27395
Study 31524941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (5 mg twice a day)
Number of subjects: 27395
Study 31524941 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once a day)
Number of subjects: 27395
Study 30488637 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic dose reduction strategy with evidence-based intensive recovery treatment (DRS+)
Number of subjects: 180
Study 30488637 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic maintenance treatment with evidence-based intensive recovery treatment (AMTx+)
Number of subjects: 180
Study 30488637 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic dose reduction strategy (DRS+)
Number of subjects: 180
Study 30488637 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic maintenance treatment (AMTx+)
Number of subjects: 180
Study 28501729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract (36mg of active component-1-deoxynojirimycin)
Number of subjects: 25
Study 28501729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornflakes with low fat milk)
Number of subjects: 25
Study 26287882 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK (Zyoptix)
Number of subjects: 48
Study 26287882 — intervention group
Group type: COMPARATOR
Intervention: Aspheric PRK (Technolas 217z)
Number of subjects: 48
Study 26287882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PRK methods
Number of subjects: 48
Study 22967208 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized intravesical ropivacaine
Number of subjects: 40
Study 22967208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 40
Study 22049410 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased theta power and decreased beta power during memory encoding
Number of subjects: 0
Study 22049410 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger activity in the left inferior prefrontal cortex and right parahippocampal gyrus
Number of subjects: 0
Study 22049410 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta power in the left inferior prefrontal cortex
Number of subjects: 0
Study 22049410 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta power in medial temporal lobe regions
Number of subjects: 0
Study 19421910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bankart repair using Mitek GI/GII anchors combined with capsular imbrication (n = 33)
Number of subjects: 66
Study 19421910 — intervention group
Group type: COMPARATOR
Intervention: Putti‐Platt procedure (n = 33)
Number of subjects: 66
Study 19421910 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable shoulders (n = 28)
Number of subjects: 66
Study 19421910 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable shoulders (n = 34)
Number of subjects: 66
Study 16123771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Number of subjects: 15
Study 15133709 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with disc hemorrhages
Number of subjects: 78
Study 15133709 — intervention group
Group type: COMPARATOR
Intervention: Eyes without disc hemorrhages
Number of subjects: 78
Study 11511434 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0
Study 9147610 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (Ida) 10 mg/m2 given as a 3 min infusion
Number of subjects: 17
Study 9147610 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin (Ida) 10 mg/m2 given as a 2 h infusion
Number of subjects: 17
Study 9147610 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (Ida) in combination with Cytosine arabinoside (Ara‐C, 1 g/m2)
Number of subjects: 17
Study 9147610 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (Ida)
Number of subjects: 17
Study 9147610 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (Ida) as prolonged infusion
Number of subjects: 17
Study 8345007 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin Sodium
Number of subjects: 14
Study 8345007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanutin
Number of subjects: 14
Study 8345007 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 300-mg dose of phenytoin at 08.00 hours
Number of subjects: 14
Study 8345007 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 300-mg dose of phenytoin at 20.00 hours
Number of subjects: 14
Study 31119515 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritist 'passe' intervention
Number of subjects: 0
Study 31119515 — intervention group
Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 0
Study 31495592 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 66
Study 31495592 — intervention group
Group type: COMPARATOR
Intervention: Tdap (control)
Number of subjects: 66
Study 28590768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroalcoholic extract of Capsella bursa pastoris
Number of subjects: 100
Study 28590768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100